The period for CME/CE credit for this activity has expired.


This activity has expired. Thank you for using WebBasedCME.com. Continue to check our activities page for additional online CME offerings .


POST-TEST - BREAKING NEWS on INCRETIN-BASED THERAPIES Summary Conference Report


INSTRUCTIONS: Select the most appropriate response. To receive credit, participants must earn a score of 80% or higher.

1. Generally speaking, which of the following statements about incretin-based therapies is not true?
A: In clinical trials, DPP-4 inhibitors reduced A1C by about 1.5%
B: DPP-4 inhibitors are associated with less nausea than incretin mimetics
C: Incretin mimetics and DPP-4 inhibitors are associated with weight loss
D: Incretin mimetics and DPP-4 inhibitors are associated with a low risk of hypoglycemia

2. GLP-1 analogs and DPP-4 inhibitors reduce ____.
A: Both fasting plasma glucose (FPG) and postprandial glucose (PPG)
B: FPG only
C: PPG only
D: PPG, but only in lean patients

3. Which of the following is true regarding DPP-4 inhibitors?
A: Most DPP-4 inhibitors also inhibit DPP-8 and DPP-9
B: Nausea is the most common side effect
C: They promote weight loss
D: They act by enhancing circulating levels of endogenous GLP-1

4. Which of the following statements about exenatide LAR is not true?
A: Weight loss was about the same as for exenatide
B: Glycemic control was better with LAR than with exenatide
C: More patients had A1C < 7% on LAR than on exenatide
D: More patients had nausea on LAR than on exenatide

5. Improvements in measures of ß-cell function have been demonstrated in clinical trials for all of the following agents except ___.
A: Exenatide
B: Liraglutide
C: Sitagliptin
D: Taspoglutide

6. Which of the following agents was shown to reduce hepatic steatosis?
A: Alogliptin
B: Liraglutide
C: Saxagliptin
D: Taspoglutide

7. In phase 3 studies, alogliptin lowered A1C by approximately ___.
A: 0.5%-0.8%
B: 0.8%-1.2%
C: 1.2%-1.5%
D: 1.5%-2.0%

8. In phase 3 studies, liraglutide 1.8 mg lowered A1C by approximately___ .
A: 0.5%-0.8%
B: 0.8%-1.0%
C: 1.0%-1.3%
D: 1.4%-1.8%

9. Which of the following antidiabetic agents was not used as a comparator in the LEAD studies?
A: Glimepiride
B: Glyburide
C: Insulin glargine
D: Rosiglitazone

10. Which of the following dosing schedules are being examined for taspoglutide?
A: Once daily and twice daily
B: Once daily and once weekly
C: Once weekly and once every 2 weeks
D: Once weekly and once monthly